Insulin Autoantibodies (IgG)

The Insulin Autoantibodies (IgG) test (IAA, insulin antibodies) is used to aid the differential diagnosis of autoimmune type 1 diabetes versus type 2 diabetes in patients who have never received exogenous insulin. In screening or research contexts, it may be used with other islet autoantibodies to estimate near-term risk of type 1 diabetes in first-degree relatives of affected patients, especially in children. This assay should not be used to distinguish autoimmune disease in individuals treated with insulin, as therapy frequently induces anti-insulin antibodies independent of endogenous autoimmunity.

Insulin autoantibodies are highly specific serologic markers of autoimmune beta-cell injury in type 1 diabetes. IAA are present in roughly half of patients at or near the time of diagnosis, occur more frequently in young children, and are often the earliest autoantibody detected at higher titers in this age group. Titers may wane over the first months after onset and can become undetectable over time. A negative IAA result does not rule out type 1 diabetes. Diagnostic yield improves when IAA are measured alongside other islet autoantibodies, such as antibodies to glutamic acid decarboxylase and islet cell antigens. In children without hyperglycemia, detection of IAA signifies immune activity rather than established disease; when combined with additional islet autoantibodies, it is associated with higher short-term risk of progression. Prior exposure to exogenous (recombinant) insulin commonly induces anti-insulin antibodies, producing positive results regardless of underlying autoimmunity; therefore, IAA testing is not appropriate for differential diagnosis in insulin-treated patients. Autoimmune thyroid disease, primary adrenal insufficiency, celiac disease, and pernicious anemia frequently co-occur with type 1 diabetes and merit targeted laboratory evaluation when autoimmune diabetes is confirmed.